Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Goodwill (2016 - 2022)

Aytu Biopharma (AYTU) has disclosed Goodwill for 7 consecutive years, with $8.6 million as the latest value for Q1 2022.

  • On a quarterly basis, Goodwill fell 77.1% to $8.6 million in Q1 2022 year-over-year; TTM through Mar 2022 was $8.6 million, a 77.1% decrease, with the full-year FY2021 number at $65.8 million, up 134.25% from a year prior.
  • Goodwill was $8.6 million for Q1 2022 at Aytu Biopharma, down from $46.3 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $65.8 million in Q2 2021 to a low of $8.6 million in Q1 2022.
  • A 4-year average of $32.9 million and a median of $28.1 million in 2020 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: surged 134.25% in 2021, then crashed 77.1% in 2022.
  • Aytu Biopharma's Goodwill stood at $15.4 million in 2019, then surged by 82.56% to $28.1 million in 2020, then skyrocketed by 65.0% to $46.3 million in 2021, then crashed by 81.37% to $8.6 million in 2022.
  • Per Business Quant, the three most recent readings for AYTU's Goodwill are $8.6 million (Q1 2022), $46.3 million (Q4 2021), and $46.3 million (Q3 2021).